Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

US Biopharma to Launch Phase 3 Trial in Bacterial Vaginosis

Daré Bioscience's study, its prospects and the indication's U.S. market opportunity are discussed in a ROTH Capital Partners report. In a May 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi reviewed why the outlook is positive for Daré Bioscience In...
Streetwise Reports | May 21, 2020 |

FDA Approval of Antibiotic for Bacterial Pneumonia Expected in Late Summer

An update on this biopharma's two lead drug candidate programs was provided in an H.C. Wainwright report. In a May 13 research note, H.C. Wainwright & Co. analyst Ed Arce reported that for Nabriva Therapeutics Plc (NBRV:NASDAQ) , "all eyes [are] on [its] Au...
Streetwise Reports | May 16, 2019 |

Paratek Pharma Awarded $285 Million BARDA Contract to Combat Anthrax

Shares of Paratek Pharmaceuticals traded 40% higher today after the firm announced it was awarded a BARDA BioShield program contract valued at up to $285 million for NUZYRA used to treat anthrax. Late yesterday afternoon, biopharmaceutical company Paratek Pharmaceuti...
Streetwise Reports | December 20, 2019 |

Biotech Firm ''Creating Innovative Solutions' for Female Health

The company's most advanced assets are discussed in a Dawson James Securities report. In a July 18 research note, Dawson James Securities analyst Jason Kolbert reported he assumed coverage on Daré Bioscience Inc. (DARE:NASDAQ) , and in doing so, rated it Bu...
Streetwise Reports | July 24, 2019 |

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/...
Streetwise Reports | November 5, 2019 |

Top Gold Stocks – January 2020

Gold is the most popular precious metal to invest in. Gold is what’s known as a “safe haven asset” where investors buy-in as a way of diversifying risk, especially through futures contracts and derivatives. Like other markets, gold is subj...
Stockhouse Editorial | July 24, 2019 |

XPhyto: Buyouts, Biosensors and a Booming Business

Test, test, test! It’s the World Health Organization’s battle cry in the global war against COVID-19 and other coronaviruses – including future outbreaks. And it is not getting any less resonant as new variants continue to cause ha...
Marc Davis | August 3, 2021 |

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned

The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report. In an Aug. 20 research note, analyst Ed Arce reported that H.C. Wainwright & Co. raised its target price on Nabriva Therapeutics Plc (NBRV:NASDAQ) to $8 per sh...
Streetwise Reports | August 28, 2019 |

T2 Biosystems Shares Nearly Double on Worldwide COVID-19 Testing License Deal

Shares of T2 Biosystems Inc. traded 90% higher after the company reported that a new COVID-19 assay licensed from Hackensack Meridian Health's Center for Discovery and Innovation will be adapted to run on its FDA-cleared T2Dx® Instrument. Diagnostic...
Streetwise Reports | March 26, 2020 |

Should We Rethink Nuclear Power?

While it seems to fly in the face of everything we believe and have been taught about nuclear power, it may actually be the safest form of power production that we have. Ironically, the immense potency of the power of splitting an atom is simultaneously what makes nuclear weap...
Haley Zaremba | March 8, 2019 |
1 2 3